Document Detail


Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
MedLine Citation:
PMID:  20883057     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Alogliptin (Nesina®) is a dipeptidyl peptidase-4 inhibitor that is approved in Japan for the treatment of adult patients with type 2 diabetes mellitus that is inadequately controlled by diet and exercise alone or by diet plus treatment with an α-glucosidase inhibitor. Alogliptin plus diet and exercise is also approved in Japan for use in combination with a thiazolidinedione in patients with type 2 diabetes. In several large (n >250), double-blind, multinational trials of up to 26 weeks' duration, oral alogliptin as monotherapy or in combination with other oral antihyperglycaemic agents (metformin, glibenclamide or pioglitazone) or insulin therapy improved glycaemic control and was generally well tolerated in adult patients with inadequately controlled type 2 diabetes, including elderly patients. Significant improvements in glycaemic control were evident from as early as 1 week in terms of improvements in mean fasting plasma glucose levels and from 4 weeks onwards for improvements in mean glycosylated haemoglobin levels. In general, the incidence of hypoglycaemia was similar to that seen in placebo groups and alogliptin treatment had neutral effects on bodyweight and lipid parameters. The long-term safety of alogliptin therapy remains to be established in clinical studies and with clinical experience. A planned clinical trial evaluating long-term clinical outcomes in patients with acute coronary syndrome and other planned or ongoing short-term trials will help to more definitively determine the position of alogliptin therapy in relation to other available antihyperglycaemic therapies. In the meantime, alogliptin is a promising new option for the treatment of patients with type 2 diabetes, including elderly patients.
Authors:
Lesley J Scott
Related Documents :
20953027 - Generalized granuloma annulare.
17493407 - Progress in the treatment of diabetes type 1 and 2.
6773727 - Efficacy of low-dose insulin therapy for severely obtunded patients in diabetic ketoaci...
1580727 - Effects of long-term anticoagulant therapy in subgroups after acute myocardial infarction.
8826967 - Glucosamine-induced inhibition of liver glucokinase impairs the ability of hyperglycemi...
499287 - Improved oral glucose tolerance following antiserotonin treatment in patients with chem...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Drugs     Volume:  70     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-04     Completed Date:  2011-01-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  2051-72     Citation Subset:  IM    
Affiliation:
Adis, a Wolters Kluwer Business, Mairangi Bay, North Shore, Auckland, New Zealand. demail@adis.co.nz
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Clinical Trials as Topic
Diabetes Mellitus, Type 2 / drug therapy*
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use*
Drug Therapy, Combination / statistics & numerical data
Humans
Hypoglycemic Agents / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Piperidines / adverse effects,  pharmacokinetics,  pharmacology,  therapeutic use*
Uracil / adverse effects,  analogs & derivatives*,  pharmacokinetics,  pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Dipeptidyl-Peptidase IV Inhibitors; 0/Hypoglycemic Agents; 0/Piperidines; 0/alogliptin; 66-22-8/Uracil
Comments/Corrections
Erratum In:
Drugs. 2010 Dec 24;70(18):2475

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypert...
Next Document:  Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult?